Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Anne Rodallec, Jean-Michel Brunel, Sarah Giacometti, Helene Maccario, Florian Correard, Eric Mas, Caroline Orneto, Ariel Savina, Fanny Bouquet, Bruno Lacarelle, Joseph Ciccolini & Raphaelle Fanciullino. (2018) Docetaxel–trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. International Journal of Nanomedicine 13, pages 3451-3465.
Read now
Read now
Alessandra Fabi, Roberta Merola, Gianluigi Ferretti, Anna Di Benedetto, Barbara Antoniani, Cristiana Ercolani, Cecilia Nisticò, Paola Papaldo, Mariangela Ciccarese, Isabella Sperduti, Patrizia Vici, Mirella Marino, Stefania Gori, Claudio Botti, Paola Malaguti, Francesco Cognetti & Marcella Mottolese. (2013) Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. Expert Opinion on Pharmacotherapy 14:6, pages 699-706.
Read now
Read now
Articles from other publishers (34)
Izzet Dogan, Esra Aydin, Nijat Khanmammadov, Nail Paksoy, Pinar Saip & Adnan Aydiner. (2023) Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression. Scientific Reports 13:1.
Crossref
Crossref
Neha Bajwa, Shipra Mahal, Preet Amol Singh, Kiran Jyoti, Pawan Dewangan, Jitender Madan & Ashish Baldi. 2023. Polymer-Drug Conjugates. Polymer-Drug Conjugates
389
469
.
Raghavendra C. Mundargi, Neetika Taneja, Jayeshkumar J. Hadia & Ajay J. Khopade. 2022. Targeted Drug Delivery. Targeted Drug Delivery
69
125
.
Sikandar ShaikhSikandar Shaikh. 2022. Advances in Imaging. Advances in Imaging
257
271
.
Amit Nautiyal, Ashish K. Jha, Sneha Mithun, Bhakti Shetye, Mythili Kameswaran, Sneha Shah, Venkatesh Rangarajan & Sudeep Gupta. (2021) Analysis of absorbed dose in radioimmunotherapy with 177Lu-trastuzumab using two different imaging scenarios: a pilot study. Nuclear Medicine Communications 42:12, pages 1382-1395.
Crossref
Crossref
Homa Seyedmirzaei, Mahsa Keshavarz-Fathi, Sepideh Razi, Masoumeh Gity & Nima Rezaei. (2021) Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2). Journal of Oncology Pharmacy Practice 27:5, pages 1235-1244.
Crossref
Crossref
Sanjoy Das & Malay K. Das. 2021. Multifunctional Theranostic Nanomedicines in Cancer. Multifunctional Theranostic Nanomedicines in Cancer
307
344
.
Zaver M. Bhujwalla, Samata Kakkad, Zhihang Chen, Jiefu Jin, Sudath Hapuarachchige, Dmitri Artemov & Marie-France Penet. (2018) Theranostics and metabolotheranostics for precision medicine in oncology. Journal of Magnetic Resonance 291, pages 141-151.
Crossref
Crossref
Cristiana Ercolani, Caterina Marchiò, Anna Di Benedetto, Alessandra Fabi, Letizia Perracchio, Patrizia Vici, Francesca Sperati, Simonetta Buglioni, Vincenzo Arena, Edoardo Pescarmona, Anna Sapino, Irene Terrenato & Marcella Mottolese. (2017) Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. Journal of Experimental & Clinical Cancer Research 36:1.
Crossref
Crossref
Alessandra Fabi, Paola Malaguti, Sabrina Vari & Francesco Cognetti. (2016) First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?. Journal of Experimental & Clinical Cancer Research 35:1.
Crossref
Crossref
Thomas Bachelot, Jose A Garcia-Saenz, Sunil Verma, Maya Gutierrez, Xavier Pivot, Mark F Kozloff, Catherine Prady, Xin Huang, Reza Khosravan, Zhixiao Wang, Rossano Cesari, Vanessa Tassell, Kenneth A Kern, Jean-Yves Blay & Ana Lluch. (2014) Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer 14:1.
Crossref
Crossref
Marek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, Hilde Revets, Nick Devoogdt, Tony Lahoutte & Michael R. Zalutsky. (2013) Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nuclear Medicine and Biology 40:1, pages 52-59.
Crossref
Crossref
Catalin Mihalcioiu. 2013. Experimental and Clinical Metastasis. Experimental and Clinical Metastasis
299
318
.
Fatima Cardoso, Jean-Luc Canon, Dino Amadori, Daniela Aldrighetti, Jean-Pascal Machiels, Yasmina Bouko, Lev Verkh, Tiziana Usari, Kenneth A. Kern, Carla Giorgetti & Luc Dirix. (2012) An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. The Breast 21:6, pages 716-723.
Crossref
Crossref
Marie-France Penet, Zhihang Chen, Samata Kakkad, Martin G. Pomper & Zaver M. Bhujwalla. (2012) Theranostic imaging of cancer. European Journal of Radiology 81, pages S124-S126.
Crossref
Crossref
Gabriela Kramer-Marek, Marcelino Bernardo, Dale O. Kiesewetter, Ulas Bagci, Monika Kuban, Aras Omer, Rafal Zielinski, Jurgen Seidel, Peter Choyke & Jacek Capala. (2012)
PET of HER2-Positive Pulmonary Metastases with
18
F-Z
HER2:342
Affibody in a Murine Model of Breast Cancer: Comparison with
18
F-FDG
. Journal of Nuclear Medicine 53:6, pages 939-946.
Crossref
Crossref
Ibere Cauduro Soares, Kleber Simões, Jorge Estefano Santana de Souza, Oswaldo Keith Okamoto, Alda Wakamatsu, Maria Carolina Tuma, Gerd Ritter & Venancio Avancini Ferreira Alves. (2012) In Silico Analysis and Immunohistochemical Characterization of NaPi2b Protein Expression in Ovarian Carcinoma With Monoclonal Antibody Mx35. Applied Immunohistochemistry & Molecular Morphology 20:2, pages 165-172.
Crossref
Crossref
Jasgit C. Sachdev & Mohammad Jahanzeb. (2012) Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer 12:1, pages 19-29.
Crossref
Crossref
Geoffrey L. Ray, Kwamena E. Baidoo, Lanea M. M. Keller, Paul S. Albert, Martin W. Brechbiel & Diane E. Milenic. (2011) Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. Pharmaceuticals 5:1, pages 1-15.
Crossref
Crossref
Rintaro Okoshi, Chung-Li Shu, Sayoko Ihara & Yasuhisa Fukui. (2011) Heregulin β-1 Induces Loss of Cell-Cell Contact and Enhances Expression of MUC1 at the Cell Surface in HCC2998 and MKN45-1 Cells. PLoS ONE 6:12, pages e29599.
Crossref
Crossref
Coralie Deladriere, Rut Lucas & María J. Vicent. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology
805
837
.
Alessandra Fabi, Anna Di Benedetto, Giulio Metro, Letizia Perracchio, Cecilia Nisticò, Franco Di Filippo, Cristiana Ercolani, Gianluigi Ferretti, Elisa Melucci, Simonetta Buglioni, Isabella Sperduti, Paola Papaldo, Francesco Cognetti & Marcella Mottolese. (2011) HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. Clinical Cancer Research 17:7, pages 2055-2064.
Crossref
Crossref
C. Vogel, A. Chan, B. Gril, S.-B. Kim, J. Kurebayashi, L. Liu, Y.-S. Lu & H. Moon. (2010) Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib. Japanese Journal of Clinical Oncology 40:11, pages 999-1013.
Crossref
Crossref
Samira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei & Fariba Johari Daha. (2010) 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nuclear Medicine and Biology 37:8, pages 949-955.
Crossref
Crossref
Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S. Lanchbury, Aysegul A. Sahin, Gabriel N. Hortobagyi & Dihua Yu. (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K Status. The American Journal of Pathology 177:4, pages 1647-1656.
Crossref
Crossref
Samira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei & Fariba Johari Daha. (2010) Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines. Applied Radiation and Isotopes 68:10, pages 1964-1966.
Crossref
Crossref
Samira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei & Fariba Johari Daha. (2010) Synthesis and biodistribution studiesof 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model. Journal of Labelled Compounds and Radiopharmaceuticals 53:9, pages 575-579.
Crossref
Crossref
Yolanda Fernández, Juan Cueva, Andrés G. Palomo, Manuel Ramos, Ana de Juan, Lourdes Calvo, Jesús García-Mata, Paula García-Teijido, Ignacio Peláez & Laura García-Estévez. (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treatment Reviews 36:1, pages 33-42.
Crossref
Crossref
Tejal A. Patel & Edith A. Perez. 2010. Management of Breast Diseases. Management of Breast Diseases
425
449
.
Kellie L Jones & Aman U Buzdar. (2009) Evolving novel anti-HER2 strategies. The Lancet Oncology 10:12, pages 1179-1187.
Crossref
Crossref
Francesca Greco & María J. Vicent. (2009) Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Advanced Drug Delivery Reviews 61:13, pages 1203-1213.
Crossref
Crossref
Giulio Francia, Shan Man, Chyan-Jang Lee, Christina R. Lee, Ping Xu, Miriam E. Mossoba, Urban Emmenegger, Jeffrey A. Medin & Robert S. Kerbel. (2009) Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts. Clinical Cancer Research 15:20, pages 6358-6366.
Crossref
Crossref
Ming-Hong Jiang, Lin Chen, Lin-Fang Li, Hong-Ping Wu, Li-Hua Jiang, Yan-Zhen Qian, Guo-En Fang & Xu-Chao Xue. (2009) A GUTLESS ADENOVIRAL VECTOR EXPRESSING FULL-LENGTH ANTI-Her2 ANTIBODY. Clinical and Experimental Pharmacology and Physiology 36:9, pages e26-e31.
Crossref
Crossref
Samira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei, Fariba Johari Daha & Mojtaba Salouti. (2009) Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nuclear Medicine and Biology 36:4, pages 363-369.
Crossref
Crossref